US Patent

US10391075 — Antiviral treatments

Method of Use · Assigned to Biocryst Pharmaceuticals Inc · Expires 2027-02-12 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects unit dosage forms, kits, and methods for treating viral infections.

USPTO Abstract

The invention provides unit dosage forms, kits, and methods useful for treating viral infections.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2622`	—

Patent Metadata

Patent number: US10391075
Jurisdiction: US
Classification: Method of Use
Expires: 2027-02-12
Drug substance claim: No
Drug product claim: No
Assignee: Biocryst Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.